✨ Free AI Report
Gritstone bio, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Gritstone bio, Inc.
Company Research

Gritstone bio, Inc.: Business Overview, Financials & Competitive Analysis

Gritstone bio, Inc. scores 2/10 on the AskCyborg Cyborg Score (Challenged). Early-stage immunotherapy platform with promising science undermined by critical financial failure and delisted status. The company filed for Chapter 11 bankruptcy in October 2024. Market capitalization stands at $3.8M with the stock declining 98.3% over the past year. The platform and pipeline remain scientifically interesting but company viability is.

What is Gritstone bio, Inc.'s industry? Gritstone bio, Inc. (gritstonebio.com) operates in Biotechnology - Immunotherapy & Oncology. AskCyborg classifies Gritstone bio, Inc. under Biotechnology - Immunotherapy & Oncology in its company registry.

Gritstone bio discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company uses self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd) vect...

2/ 10Challenged

Cyborg Score thesis

Early-stage immunotherapy platform with promising science undermined by critical financial failure and delisted...

Read the full analyst-debate transcript →
Industry Biotechnology - Immunotherapy & Oncology
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: September 14, 2026
AI-Verified Research
30+ Page Report

Get the Latest Gritstone bio, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Gritstone bio, Inc.

AskCyborg analysts argue the bull and bear cases for Gritstone bio, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Gritstone bio, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Gritstone bio, Inc. Overview

Pro stress-test →

Gritstone bio discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company uses self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd) vectors to elicit desired immune responses. The company faces severe financial distress following bankruptcy restructuring.

Strategic Profile

Pro stress-test →

The company's two oncology programs in clinical-stage development are GRANITE, an individualized neoantigen-based immunotherapy, and SLATE, an off-the-shelf shared neoantigen-based immunotherapy. The company has also developed a COVID-19 vaccine candidate supported by U.S. government contracts and is researching a functional cure for HIV in collaboration with the National Institutes of Health.

Competitive Landscape

Pro stress-test →

Gritstone competes in the personalized cancer immunotherapy and vaccine development space against larger, better-capitalized biotechs including Moderna, BioNTech, and Inovio. However, bankruptcy and delisting have effectively removed it from active competition. The company's neoantigen-personalized approach competes conceptually with similar therapies from larger oncology platforms.

Industry Context

Gritstone bio, Inc. operates in Biotechnology - Immunotherapy & Oncology.

Key facts

Founded: 2015 · Headquarters: Emeryville, US · Market cap: $3.8M

What the analysts stress-tested

The top findings that survived the multi-agent debate for Gritstone bio, Inc..

  • Proprietary samRNA and ChAd vector platforms target cancer neoantigens and infectious diseases
  • Significant financial deterioration: Chapter 11 bankruptcy filed (October 2024), stock down 98.3% year-over-year
+2 more stress-tested counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • October 2024Filed for Chapter 11 bankruptcy
  • Stock price declined to penny stock levels (below $0.05 by late 2024)
  • +1 moreTrack every material event for Gritstone bio, Inc. as it happens. Explore monitoring →
Get alerted when Gritstone bio, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

ModernamRNA-based therapeutics and vaccines→BioNTechPersonalized neoantigen immunotherapies→InovioDNA vaccine platform→

Compare Gritstone bio, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Gritstone bio, Inc. operates in Biotechnology - Immunotherapy & Oncology. See how the rest of the sector scores on the Cyborg framework.

Browse Biotechnology - Immunotherapy & Oncology research →
NEW · MCP server

Ask your AI assistant about Gritstone bio, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Gritstone bio, Inc. and its top competitor on Cyborg Score”
“What did Gritstone bio, Inc. do this quarter?”
“Is Gritstone bio, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg builds confidence

⚔

Analyst debate, not single-author opinion

Every report is stress-tested by a panel of AI analysts arguing across 11 dimensions. The output is the part of the case that survived pushback.

📊

Recalibrated weekly

The Cyborg Score is recomputed weekly against fresh data. Recent material developments are continuously tracked and surfaced.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The same company gets the same score from any analyst running the framework.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, news flow, and proprietary analyst signals. Read the methodology →

Frequently asked questions

What does Gritstone bio, Inc. do?+
Gritstone bio discovers, develops, manufactures and delivers next generation cancer and infectious disease immunotherapy candidates. The company uses self-amplifying mRNA (samRNA) and chimpanzee adenovirus (ChAd) vect...
What is Gritstone bio, Inc.'s Cyborg Score?+
Gritstone bio, Inc. has a Cyborg Score of 2/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Gritstone bio, Inc.'s main competitors?+
Named competitors include Moderna, BioNTech, Inovio. The full competitive landscape is in the AskCyborg report.
How can I get the full Gritstone bio, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Gritstone bio, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Gritstone bio, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology - Immunotherapy & Oncology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

4Moderna, Inc.7BioNTech SE